CTLA4 and osteosarcoma: Additionally, Helm et al. found that osteosarcoma mouse models treated with a combination of CTLA-4 and PD-1 immune checkpoint inhibitors showed a rise in CD8+ T cells, increasing the cytotoxicity in the tumor microenvironment and contributing to a better prognosis [239].